Gain Therapeutics

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.

Dogma Biotech

This company develops AI-designed glycans to enhance protein therapeutic performance for patients with central nervous system and lysosomal storage diseases.

NeurOdys Therapeutics

This biotechnology company develops small molecule therapies for patients with neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.

Pangea Bio

This biotechnology company develops small molecule medicines for neurological and neuropsychiatric disorders using an artificial intelligence platform to identify compounds from natural sources.

Exin Therapeutics

This company develops an artificial intelligence platform to discover and design neurotherapeutics targeting neural circuits for patients with neurological and neuropsychiatric disorders.

Dewpoint Therapeutics

This biotechnology company develops condensate-modifying small molecule drugs for patients with oncology, neurodegenerative, cardiopulmonary and metabolic diseases using an AI-enabled discovery platform.

Ten63 Therapeutics

This company develops small-molecule drugs for pharmaceutical partners and patients using a generative artificial intelligence and physics-based chemistry platform to treat undruggable protein targets.

Auron Therapeutics

This company develops small-molecule drugs using an AI-powered platform to treat patients with cancer and inflammatory diseases.